Classes of Respiratory Medications

Respiratory pharmacology includes bronchodilators anti inflammatory agents mucolytics and agents that modify secretions and each class targets specific pathophysiological mechanisms to improve airflow gas exchange and symptom control. Short acting and long acting beta agonists relax airway smooth muscle and provide rapid relief or maintenance control while anticholinergic agents reduce bronchoconstriction through vagal blockade. Inhaled corticosteroids reduce airway inflammation and are central to management of chronic inflammatory airway disease and systemic corticosteroids are used for acute exacerbations. Mucolytics and expectorants alter sputum properties to facilitate clearance and adjunctive therapies such as antibiotics and antifungals treat infectious contributors. Understanding pharmacokinetics delivery routes and potential interactions supports safe and effective therapy.

Delivery Routes and Device Considerations

Delivery route influences onset and systemic exposure and inhaled delivery targets the airways directly and reduces systemic side effects when compared with oral or intravenous routes. Device selection affects deposition and patient adherence and includes metered dose inhalers dry powder inhalers and nebulizers and clinicians match device to patient ability and to medication formulation. Spacer devices improve metered dose inhaler performance and nebulizer choice considers particle size residual volume and compatibility with ventilator circuits. Education on inhaler technique and on adherence monitoring is essential to achieve therapeutic goals and periodic review of medication lists reduces polypharmacy and adverse events.

Monitoring Efficacy and Safety

Monitoring medication efficacy uses symptom assessment lung function measures and exacerbation frequency and safety monitoring includes observation for side effects such as tachycardia tremor oral candidiasis and systemic steroid complications. Therapeutic drug monitoring is required for select agents and clinicians adjust therapy based on response and on comorbid conditions such as cardiovascular disease or diabetes. Patient education on expected benefits potential side effects and on when to seek medical attention improves adherence and reduces preventable harm. Documentation of medication changes and of rationale supports continuity of care and multidisciplinary management.